Introduction
The mechanism underlying the beneficial effect of bariatric surgery still remains unclear. Changes in incretin hormone levels are proposed to be important consequence of that treatment. Ghrelin is a gastroen teric hormone with the strongest orexigenic signal [1] , whose levels are affected by bariatric treatment [2] . It is known that ghrelin exists in two different forms: acylated (acyl ghrelin -AG) and desacylated (des acyl ghrelin -DAG). Desacyl ghrelin was long con sidered to be an inactive degradation product of the Fasting and postprandial acyl and desacyl ghrelin and the acyl/desacyl ratio in obese patients before and after different types of bariatric surgery Jolanta A. Dardzińska 1 acylated form, but emerging evidence suggests that the desacylated form of ghrelin may induce meta bolic effects independently of AG. The interactions between both isoforms may be important in the en ergy balance [3, 4] . It is also important to assess the fasting as well as postprandial level of both ghrelin isoforms, because they are obviously affected by food intake and their proportions can be changed in obesity [5, 6] . There are suggestions that obese people with metabolic syndrome have a higher acyl/ desacyl ratio (AG/DAG) [7] and that this ratio may be modulated by some form of medical intervention [8] . Probably ghrelin isoform changes may be an import ant element of the metabolic response to bariatric treatment.
Recently, there has been dynamic development of bariatric surgery and a rapid increase in the num ber of procedures performed.
There are different kinds of operations -not only the commonly accepted RouxenY gastric bypass (RYGB) and sleeve gastrectomy (SG), but also the novel mini gastric bypass (MGB) [9, 10] . The afore mentioned procedures are presented in Figure 1 . Their mechanisms of action may vary depending on the different changes in the anatomy of the digestive tract ( Figure 1 ) -from SG where no biliary exclusion is performed to MGB with significantly increased length of the biliary limb [11, 12] . As for hormonal changes, especially ghrelin, most of the data are for RYGB and some for SG [13, 14] , but there is a lack of data on hormonal effects of MGB [15] .
Aim
The aim of this study was to evaluate pre and postprandial changes in both ghrelin isoforms in obese patients without diabetes and cardiovascular complications treated with MGB, SG or RYGB surgery.
Material and methods
Fortyfive patients (34 female/11 male) with sim ple obesity, without cardiovascular events in anam Figure 1 . The schematic presentation of sleeve gastrectomy (SG), RouxenY gastric bypass (RYGB) and Mini Gastric Bypass (MGB) from [16] nesis, not taking any diabetic medicaments, were accepted initially for surgery and enrolled in the prospectively designed study. They were selected from patients who reported to the Outpatient Clinic of the Department of General, Endocrine and Trans plant Surgery, Medical University of Gdansk, Poland, in 2013-2014 with the purpose of surgical obesity treatment. All patients met IFSO criteria [16] . The inclusion criteria for the study were the maximum body mass index (BMI) > 35 kg/m 2 and informed consent to participate in the study.
The exclusion criteria included use of antidiabetic medications, history of cardiovascular events, chronic liver or kidney disease and pregnancy. The study was approved by the university ethics committee.
Only 31 patients followed the requirements of the study and qualified finally for surgery at that time. They were operated on after a standard 3month preparation period. The RYGB procedure was offered to 11 subjects with lower oesophageal sphincter dysfunction. Twelve others were quali fied for the MGB and 8 persons for the SG. For both types of gastric bypass the restriction was provided by a long, narrow (calibrated for 36 F) 50 ml gas tric pouch. The length of the alimentary limb (AL) in RYGB patients was maintained for 150 cm and respectively 50 cm for the excluded biliary limb (BL) while in MGB the biliary transit was designed for 200 cm. The common limb (CL) was proportionally left the same in both operations. In contrast to the bypass procedures there is no jejunal exclusion in SG, but 80-90% of the stomach capacity is resected. The size of the pouch in the SG procedure has also been determined by the 36 F calibration tube, the same as it has been used for both subtypes of by pass. The first stapler was launched 4 cm proximally to the pylorus. The volume of the stomach reservoir was measured for 60 ml. A detailed description of 45 patients accepted initially to surgery and enrolled to the study 31 patients qualified finally to surgery and followed the requirements of the study the surgical technique has been included in a pre vious publication from our institution [16] . The in tra and postoperative course was uneventful in all patients. From 31 subjects, 8 (2 from RYGB, 3 from MGB and 3 from SG group) had to be excluded from the study. The reasons for exclusion and the study flow chart are presented in Figure 2 . Anthropometric examination and blood sam pling were performed at the beginning of the study (3 months before the surgery) and then 6 and 12 months after surgery. In all patients in the fast ing state the waist circumference, weight and body composition were measured. The percentage of fat tissue (FAT %), fat mass (FM), and fatfree mass (FFM) were assessed using the bioelectrical imped ance method (TANITA SC 330). The BMI (BMI = body weight (kilograms)/height (meters) 2 ) and fatfree mass index (FFMI: fatfree mass (kilograms/height (meters) 2 ), were then calculated. The venous blood was collected after a 12hour period of fasting, then patients received a standard mixed meal containing 300 kcal, 16% protein, 49% carbohydrate and 35% fat (Nutridrink standard 200 ml, Nutricia). Venous blood sampling was re peated 2 h after the start of the meal (MMTT, mixed meal tolerance test) [17] .
Plasma desacylated and acylated ghrelin levels were measured with a commercial enzyme immu noassay (Human Acylated Ghrelin EIA Kit, Human Unacylated Ghrelin EIA Kit, Biovendor, Czech Repub lic) in accordance with the supplier's specifications. Blood samples were immediately centrifuged at 3500 × g for 10 min at +4°C and serum was kept at -80°C until further analyses were performed. Glucose was measured by the hexokinase method (Abbott Laboratories, USA). Serum lipid concentra tions were measured by the oxidase method (Abbott Laboratories, USA) and the Friedewald formula was used to calculate the LDLCH concentration. Serum insulin levels were determined by EIA (Abbott Labo ratories, USA). Serum HbA 1c levels were assessed by a Tosoh G8 HPLC Analyser (TOSOH, Japan).
Insulin resistance was then estimated using the homeostasis model assessment (HOMAIR), which was calculated in line with the following formula: fast ing insulin (μU/ml) × fasting glucose (mg/dl)/405 [18] .
Statistical analysis
The data are expressed as the mean ± SD or median (range). The KolmogorovSmirnov test was used to verify whether the variable distribu tion was normal. Differences between means were evaluated by the independent Student's t test and the MannWhitney U test was used when the distribution of the variable was not normal. Fasting and postprandial values were compared using the paired Student's t test and Wilcoxon's signedrank test was used when the distribution of the variable was not normal. Spearman's rank correlation coefficient (r) was used to evaluate the relationships between the variables. The Friedman ANOVA was used for comparison of continuous data with repeated measures, and to perform the comparison between multiple groups the Krus kalWallis test was used. Statistical analysis was performed using Statistica version 12 (StatSoft, Po land). Pvalues < 0.05 were considered statistically significant.
Results
At the beginning of the study, the mean BMI among 45 participants was 45.7 ±6.7 kg/m 2 (range: 32.5-56.6 kg/m 2 ), waist circumference: 118.1 ±14.5 cm (range: 94-148 cm) and HOMAIR: 3.1 ±1.7 (range: 1.2-11.3). The characteristics of the whole study group at the beginning are shown in Table I . The MGB, RYGB and SG groups did not differ in age and metabolic parameters at the baseline.
Metabolic and hormonal changes in all patients after bariatric treatment
A year after the bariatric treatment the mean decreases in weight and BMI in all patients were 40.6 kg (123.0 vs. 82.4 kg; p < 0.05) and 14.6 kg/m 2 (43.5 vs. 28.9 kg/m 2 ; p < 0.005), respectively. The mean reduction in FM was 31.8 kg (56.5 kg vs. 24.7 kg; p < 0.005) and in FFM 8.9 kg (66.5 kg vs. 57.6 kg; p < 0.005). HOMAIR decreased after sur gery by 1.1 (2.6 vs. 1.6; p < 0.05).
Fasting DAG level decreased from 268.5 ±163.0 pg/ml to 197.7 ±140.7 pg/ml after 6 months and to 158.8 ±141.8 pg/ml 12 months after bariatric sur gery (p < 0.05). However, the postprandial DAG level and AG levels (both fasting and postprandial) did not change after the surgery in the whole study group. Similarly, we did not find statistical changes in the AG/DAG ratio after bariatric treatment. All metabolic and hormonal parameters before and after bariatric treatment are presented in Table II .
Comparison of metabolic changes between different types of surgery
In all groups (MGB, RYGB and SG) we observed beneficial metabolic outcomes (data included in Ta ble III). The grade of BMI reduction and changes in body composition at 6 and 12 months after the sur gery did not differ significantly between the groups. There were some differences between carbohydrate metabolism indices after MGB in comparison to the rest of participants. At 6 months after the surgery the HbA 1c level was lower in the MGB group than the RYGB group (4.9 ±0.3% vs. 5.2 ±0.3%, p < 0.02). Also HOMAIR and fasting insulinaemia after 6 months were lower in the MGB group than the SG group: 1.3 ±0.5 vs. 1.8 ±0.4 (p = 0.029) and 5.8 ±2.3 μU/ml vs. 8.7 ±1.9 μU/ml (p = 0.015) respectively. However, these differences were not found 12 months after the surgery.
The only significant metabolic changes after 6 and 12 month between the studied groups were found for total cholesterol (RYGB vs. SG: 149.1 ±23.2 mg/dl vs. 195.8 ±37.2 mg/dl; p = 0.009 and 159.4 ±32.0 mg/dl vs. 193 ±13.5 mg/dl; p = 0.043 respec tively) and LDL cholesterol levels (RYGB vs. SG: 90.4 ±16.5 mg/dl vs. 114.8 ±30.7 mg/dl; p = 0.07 and 95.6 ±24.7 mg/dl vs. 120.0 ±21.5 mg/dl; p = 0.08 respectively).
Changes of ghrelin isoforms after different types of surgery
AG and DAG levels (both fasting and prandi al) as well as AG/DAG ratio did not change after 6 and 12 months in MGB and RYGB groups. In the SG group we observed a significant decrease in fast ing and postprandial DAG levels and consecutively an increase in the fasting AG/DAG ratio after 6 and 12 months (data included in Table IV ). There were significant differences in fasting DAG level and post prandial DAG level between SG and RYGB groups af ter 6 months: 85.9 ±14.3 pg/ml vs. 263.1 ±155.0 pg/ ml (p = 0.009) and 52.2 ±22.3 pg/ml vs. 159.6 ±99.6 pg/ml (p = 0.014) respectively. After 12 months we also found lower fasting and postprandial DAG levels in the SG group than the RYGB group (data in Ta ble IV; p = 0.02). The postprandial AG/DAG ratio was also significantly higher in the SG than the RYGB group after 6 months: 0.34 (0.17-0.66) vs. 0.15 (0.12-0.66) (p = 0.002) and 12 months after the sur gery (data in Table IV ). We also found in the SG group in comparison to the MGB group lower fasting DAG (85.9 ±14.3 pg/ml vs. 178.3 ±112.2 pg/ml; p = 0.04) and fasting AG levels (16.6 ±2.5 pg/ml vs. 31.9 ±14.0 pg/ml; p = 0.012) after 6 months, but there were no significant differences between SG and MGB groups in both isoforms of ghrelin levels after 12 months.
Discussion
Bariatric surgery is nowadays the only effective treatment for severe obesity and such comorbidi ties as diabetes mellitus, but the exact mechanisms underlying the beneficial outcomes still remain un clear. It is proposed that hormonal changes induced by the surgery might be involved, especially ghrelin, the strongest peripheral orexigenic hormone, pro duced primarily in the stomach. It is not obvious how the RYGB procedure influences ghrelin levelsthe data are conflicting [13, 14, 19, 20] . We know even less about the effects of MGB, a novel bariatric procedure, on ghrelin levels. Hence the aim of the study was to evaluate fasting and postprandial lev els of both ghrelin isoforms after MGB, RYGB and SG, which is also commonly used in bariatric treatment. To our knowledge, there are only two reports about the effects of MGB on ghrelin levels [21, 22] . They cover a total of 6 pediatric patients with a ge netically conditioned morbid obesity in the course of PraderWilli syndrome (PWS). The MGB proce dure appeared to reduce fasting acyl ghrelin levels and provided effective weight reduction in those patients. PraderWilli syndrome is known to be char acterized by the presence of hyperghrelinemia, and simple obesity is associated with reduced ghrelin levels [2, 6] . According to available data we demon strated for the first time that levels of both ghrelin isoforms (in the fasting state as well as prandial) did not change in a year of observation after MGB. We also observed that ghrelin levels did not change af ter RYGB. We found, however, that SG leads to a de crease in desacyl ghrelin levels, which is not a sur prise as the resection of the stomach with oxyntic cells is an essential part of the SG procedure. Howev er, we did not observe any changes in the degree of weight loss after SG and the other procedures.
It was reported by Barazzoni that obese people with metabolic syndrome have a higher acyl/desacyl ratio [7] . However, in our earlier study we found the opposite -the fasting AG/DAG ratio was significantly higher in nonobese controls than in obese nondia betic patients [6] . In spite of those discrepancies, it is not explained how bariatric procedures modulate the AG/DAG ratio [23] . In our 1year observation study the AG/DAG ratio did not change after RYGB or after MGB and increased significantly after SG in the fasting but not in the postprandial state. The grade of BMI reduction and changes in body composition did not differ significantly between the groups. We can conclude that probably ghrelin isoform chang es are not so important in beneficial metabolic out comes induced by bariatric surgery. Some of our re sults may suggest, however, that the MGB procedure might be the most beneficial for patients with insulin resistance, as we observed at 6 months after the sur gery lower fasting insulinaemia, HbA 1c and HOMAIR in the MGB group. However, these differences were not significant 12 months after the surgery. We also reported previously decreased level of postprandial insulinaemia in the MGB group after 6 months from the surgery [15] . These observations comply with the concept of bile acids as a novel "hormone" [14] , as the MGB procedure can be associated with in creased circulating bile acid concentrations because of the significantly increased length of the biliary limb [11, 12] , and probably ghrelin does not mediate in that mechanism.
The important limitation of our study is the small number of participants. Because of that some differ ences could not reach statistical significance.
Conclusions
The results of this study demonstrate that all studied bariatric procedures can reduce overall body weight. The data also suggest that the mechanisms of weight loss and improvement in carbohydrate and lipid metabolism after all three types of surgery are independent of ghrelin. Prospective randomized studies based on a larger number of patients and a longer followup period are needed to establish the role of ghrelin after bariatric surgery.
